CommercialCoverageMedium impact
08.00.10d, Luspatercept–aamt (Reblozyl®)
Independence Blue Cross·Hematology, Oncology, Pharmacy·Pharmacy
Effective date
Jan 17, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.10d for Luspatercept–aamt (Reblozyl®) has been updated effective January 17, 2025. This pharmacy policy change affects coverage criteria, medical necessity requirements, billing codes, and general reimbursement guidelines for this drug. The billing team must review updated medical necessity documentation requirements and any coding changes to ensure compliant claims submission.
Action Required
By January 17, 2025: Billing team must obtain and review the complete policy text at the provided URL to identify specific medical necessity criteria, prior authorization requirements, and any HCPCS codes affected (likely J-codes for drug administration). Update billing system rules and prior authorization workflows accordingly. Ensure providers understand documentation requirements for Reblozyl claims. Contact the payer if specific codes and requirements are unclear. Claims submitted without proper medical necessity documentation may be denied.